Astuprotimut-R (Zastumotide)

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameAstuprotimut-R (Zastumotide)
Drug Alias NameZumagevSB-249553GSK-249553NSC-719274SID-534984 +[8] 
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionImmunostimulantsMelanoma-associated antigen 3 modulators
TargetsMelanoma-associated antigen 3
Therapy Area/IndicationsUrinary Bladder NeoplasmsCarcinoma, Non-Small-Cell LungMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[41] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesLudwig Institute For Cancer Research
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline PlcLudwig Center For Cancer Research Of Lausanne
Active IndicationsN/A
Inactive IndicationsUrinary Bladder NeoplasmsCarcinoma, Non-Small-Cell LungMelanoma

Other Information

ATC CodeN/A
Related LinksN/A